Q4 Earnings Forecast for TENX Issued By Leerink Partnrs

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Research analysts at Leerink Partnrs issued their Q4 2024 earnings per share (EPS) estimates for Tenax Therapeutics in a report released on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger forecasts that the specialty pharmaceutical company will post earnings per share of ($1.23) for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ Q1 2025 earnings at ($1.68) EPS, Q2 2025 earnings at ($1.92) EPS, Q3 2025 earnings at ($2.31) EPS, Q4 2025 earnings at ($2.38) EPS, FY2025 earnings at ($8.29) EPS, FY2026 earnings at ($3.91) EPS, FY2027 earnings at ($4.15) EPS and FY2028 earnings at ($2.69) EPS.

A number of other research firms have also commented on TENX. Leerink Partners initiated coverage on Tenax Therapeutics in a research report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target for the company. StockNews.com initiated coverage on shares of Tenax Therapeutics in a research note on Thursday, September 26th. They set a “sell” rating on the stock. William Blair started coverage on shares of Tenax Therapeutics in a research note on Monday, September 30th. They issued an “outperform” rating for the company. Finally, Guggenheim assumed coverage on Tenax Therapeutics in a report on Monday, October 14th. They set a “buy” rating and a $16.00 target price on the stock. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Tenax Therapeutics Trading Down 1.4 %

TENX opened at $4.87 on Monday. The stock has a 50-day moving average price of $3.99 and a 200-day moving average price of $3.69. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $41.92.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Sphera Funds Management LTD. bought a new position in shares of Tenax Therapeutics in the 3rd quarter worth approximately $101,000. Stonepine Capital Management LLC bought a new position in Tenax Therapeutics in the 3rd quarter worth $173,000. Finally, Vestal Point Capital LP purchased a new position in Tenax Therapeutics during the third quarter valued at $288,000. 1.67% of the stock is owned by hedge funds and other institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.